Cargando…
Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?
The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901091/ https://www.ncbi.nlm.nih.gov/pubmed/24710421 http://dx.doi.org/10.3390/cells1020153 |
_version_ | 1782300796801515520 |
---|---|
author | Nordberg, Marika Forsberg, Pia Nyman, Dag Skogman, Barbro H. Nyberg, Clara Ernerudh, Jan Eliasson, Ingvar Ekerfelt, Christina |
author_facet | Nordberg, Marika Forsberg, Pia Nyman, Dag Skogman, Barbro H. Nyberg, Clara Ernerudh, Jan Eliasson, Ingvar Ekerfelt, Christina |
author_sort | Nordberg, Marika |
collection | PubMed |
description | The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB. |
format | Online Article Text |
id | pubmed-3901091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-39010912014-04-07 Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Nordberg, Marika Forsberg, Pia Nyman, Dag Skogman, Barbro H. Nyberg, Clara Ernerudh, Jan Eliasson, Ingvar Ekerfelt, Christina Cells Article The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB. MDPI 2012-06-08 /pmc/articles/PMC3901091/ /pubmed/24710421 http://dx.doi.org/10.3390/cells1020153 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Nordberg, Marika Forsberg, Pia Nyman, Dag Skogman, Barbro H. Nyberg, Clara Ernerudh, Jan Eliasson, Ingvar Ekerfelt, Christina Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? |
title | Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? |
title_full | Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? |
title_fullStr | Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? |
title_full_unstemmed | Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? |
title_short | Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? |
title_sort | can elispot be applied to a clinical setting as a diagnostic utility for neuroborreliosis? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901091/ https://www.ncbi.nlm.nih.gov/pubmed/24710421 http://dx.doi.org/10.3390/cells1020153 |
work_keys_str_mv | AT nordbergmarika canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT forsbergpia canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT nymandag canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT skogmanbarbroh canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT nybergclara canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT ernerudhjan canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT eliassoningvar canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis AT ekerfeltchristina canelispotbeappliedtoaclinicalsettingasadiagnosticutilityforneuroborreliosis |